The anticholinergic anti-Parkinson drug Norakin selectively inhibits influenza virus replication.
Schroeder
C
C
Heider
H
H
Hegenscheid
B
B
Schöffel
M
M
Bubovich
V I
VI
Rosenthal
H A
HA
D000547:Amantadine / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents; D001712:Biperiden / Q000494:pharmacology*; D002460:Cell Line; D002642:Chick Embryo; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D005814:Genes, Viral / Q000187:drug effects; D006387:Hemagglutination, Viral / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D009980:Influenza A virus / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D007370:Interferon Type I / Q000096:biosynthesis; D007372:Interferons / Q000494:pharmacology; D008459:Measles virus / Q000187:drug effects; D009154:Mutation; D010880:Piperidines / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D007370:Interferon Type I; D010880:Piperidines; D001712:Biperiden; C046667:triperiden; D007372:Interferons; D000547:Amantadine